EU/3/13/1139: Orphan designation for the treatment of amyotrophic lateral sclerosis
Table of contents
On 19 June 2013, orphan designation (EU/3/13/1139) was granted by the European Commission to Shore Limited, United Kingdom, for sodium chlorite (also known as NP001) for the treatment of amyotrophic lateral sclerosis.
The sponsorship was transferred to FGK Representative Services GmbH, Germany in December 2017.
Treatment of amyotrophic lateral sclerosis
|Orphan designation status||
|EU designation number||
|Date of designation||
FGK Representative Services GmbH
Tel. +49 89 89 31 19 22
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: